| 1. |
Guidelines for the management of patients with thrombosis have been updated and released by the American College of Chest Physicians (ACCP). |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1458,
2004,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 2. |
Revise lipid-lowering guidelines, says US consumer group |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1458,
2004,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 3. |
QOL news from the 40th Annual Meeting of the EASD |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1458,
2004,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 4. |
Anti-D-Rh0-immunoglobulin: routine antenatal use worth it? |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1458,
2004,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 5. |
Visilizumab*shows promising activity in patients with severe ulcerative colitis, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1458,
2004,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 6. |
RIO-Europe adds further weight for rimonabant |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1458,
2004,
Page 7-8
S Sullivan,,
Preview
|
|
摘要:
The benefits of rimonabant [Acomplia] in overweight and obese patients were confirmed by first year results of the RIO-Europe study presented at the 26th Annual Congress of the European Society of Cardiology (ESC) [Munich, Germany; August-September 2004]. Rimonabant, a selective cannabinoid type-1 receptor antagonist, was shown to reduce bodyweight and waist circumference, and improve lipid profiles in patients with a body mass index (BMI) of > 27 kg/m2. Furthermore, the proportion of patients with metabolic syndrome was significantly reduced among those taking rimonabant, compared with the placebo group.
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 7. |
Natalizumab maintains response in Crohn's disease |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1458,
2004,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 8. |
Antioxidant supplements may not prevent cancer after all |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1458,
2004,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 9. |
ERCC1 C8092Apolymorphism may predict overall survival in NSCLC |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1458,
2004,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 10. |
Insulin glargine improves glycaemic control in type 1 and 2 diabetes |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1458,
2004,
Page 11-12
S Sullivan,,
Preview
|
|
摘要:
Insulin glargine [Lantus] is effective in improving glycaemic control in patients with type 1 and type 2 diabetes mellitus (DM), according to studies presented at the 40th Annual Meeting of the European Association for the Study of Diabetes (EASD) [Munich, Germany; September 2004]. The AT.LANTUS trial, comparing two dose titration algorithms in patients with poorly controlled DM, showed that insulin glargine significantly reduced HbA1cand fasting blood glucose levels from baseline. The incidence of severe hypoglycaemia was low among both the algorithm groups.
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
首页
